LUYE PHARMA (02186): Ruoxinlin successfully renewed in the National Reimbursement Drug List
LUYE PHARMA (02186) announced that Ruoxinlin (Toludesvenlafaxine Hydrochloride Extended-Release Tablets), a Class 1 innovative drug, has successfully been renewed on the "National Drug List for Basic Medical Insurance, Work-Related Injury Insurance and Maternity Insurance (2026)" (the 2026 National Reimbursement Drug List) for the treatment of depression.
LUYE PHARMA (02186) announced that Ruoxinlin (Toludesvenlafaxine Hydrochloride Extended-Release Tablets), a Class 1 innovative drug, has successfully been renewed on the "National Reimbursement Drug List for Basic Medical Insurance, Maternity Insurance, and Work-Related Injury Insurance (2026)" (2026 National Reimbursement Drug List) for the treatment of depression.
It is reported that Ruoxinlin was approved for marketing in China in November 2022 and was first included in the National Reimbursement Drug List in November 2024. The product is China's first independently developed Class 1 innovative chemical drug for the treatment of depression with independent intellectual property rights, achieving a breakthrough for domestic innovative drugs in this therapeutic area. As a serotonin (5-HT), norepinephrine (NE), and dopamine (DA) reuptake inhibitor (SNDRI), Ruoxinlin can comprehensively and stably treat depression, significantly improving patients' anxiety states, retardation/fatigue symptoms, anhedonia, and cognitive function, promoting the recovery of social functioning, and has good safety and tolerability, without causing drowsiness or affecting sexual function, body weight, and lipid metabolism.
With its clear clinical value, Ruoxinlin, as the only SNDRI-class antidepressant currently available, has been listed as a first-line recommended medication in the "Guidelines for the Prevention and Treatment of Depressive Disorders in China (2025 Edition)" and the "Guidelines for Community-Based Prevention and Treatment of Depression in China." In addition, the marketing application for Ruoxinlin for the treatment of generalized anxiety disorder has been accepted by the Center for Drug Evaluation of the National Medical Products Administration in January 2026.
The Group believes that the successful renewal of Ruoxinlin on the National Reimbursement Drug List will help continuously reduce patients' medication burden, further expand the product's market coverage, and broaden space for its long-term growth. The central nervous system (CNS) is a therapeutic area in which the Group has long been deeply engaged. The Group will continue to advance innovative research and development around unmet clinical needs and promote the global development and commercialization of CNS innovative drugs.
Related Articles

BEKE-W (02423) repurchased 422,900 shares for US$2.5 million on November 13.

Guangdong Shenling Environmental Systems (301018.SZ) plans to participate in bidding for land use rights to meet its development needs in the liquid cooling and temperature control field.

INNOVENT BIO (01801): Sintilimab ZYBRIVO receives positive CHMP opinion recommending approval for first-line treatment of non-squamous non-small cell lung cancer
BEKE-W (02423) repurchased 422,900 shares for US$2.5 million on November 13.

Guangdong Shenling Environmental Systems (301018.SZ) plans to participate in bidding for land use rights to meet its development needs in the liquid cooling and temperature control field.

INNOVENT BIO (01801): Sintilimab ZYBRIVO receives positive CHMP opinion recommending approval for first-line treatment of non-squamous non-small cell lung cancer






